Influence of Autologous In Vitro Activation of Ovaries by Stem Cells and Growth Factors on Endocrine and Reproductive Function of Patients with Ovarian Insufficiency-A Clinical Trial Study

Document Type : Original Article


1 Department of Gynecology, Polyclinic, Korak do Života, Tuzla, Bosnia and Herzegovina

2 Department of Regenerative Medicine, Remedika Hospital, Belgrade, Serbia

3 Department of Gynecology, MediGroup Hospital, Belgrade, Serbia

4 Faculty of Medicine, Military Medical School, Belgrade, Serbia

5 Department of Gynecology and Obstetrics, Medical School, University of Belgrade, Belgrade, Serbia

6 Department of Medical Biology and Human Physiology, Sarajevo Medical School, University Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina

7 Department of Histology, Medical School, University of Tuzla, Tuzla, Bosnia and Herzegovina

8 Department of Gynecology, Dubrovnik International University, Dubrovnik, Croatia


Premature ovarian failure (POF) can be found in 1% of women at the age of 35-40, mostly due to unknown
causes. PI3K-Akt signaling is associated with both ovarian function and growth of primordial follicles. In this
study, we examined the effects of autologous in vitro ovarian activation with stem cells and autologous growth factors
on reproductive and endocrine function in patients with ovarian impairment.

Materials and Methods:
The longitudinal prospective observational study included 50 patients (between 30 and 50
years) with a diagnosis of POF and infertility. This multicenter study was performed at Jevremova Special Hospital in
Belgrade, Saint James Hospital (Malta), and Remedica Skoplje Hospital, between 2015 and 2018. All patients went
through numerous laboratory testings, including hormonal status. The autologous bone marrow mesenchymal stem
cells (BMSCs) and growth factors were used in combination for activation of ovarian tissue before its re-transplantation.
The software package SPSS 20.0 was used for statistical analysis of the results.

Differences in follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and progesterone
(PG) hormone concentrations before and after 3, 6, and 12 months post-transplantation were tested in correlation
with the volume of transplanted ovarian tissue. A significant correlation (P=0.029) was found between the change in
E2 level after 3 months and the volume of re-transplanted tissues. Also after re-transplantation, 64% of the patients
had follicles resulting in aspiration of oocytes in 25% of positive women with follicles.

The SEGOVA method could potentially solve many human reproductive problems in the future due to
the large number of patients diagnosed with POF, as well asthe possibility of delaying menopause, thus improving
the quality of life and general health (Registration number: NCT04009473).


1. Broekmans FJ, Knauff EAH, te Velde ER, Macklon NS, Fauser BC. Female reproductive ageing: current knowledge and future trends. Trends Endocrinol Metab. 2007; 18(2): 58-65.
2. Silva JRV, van den Hurk R, van Tol HTA, Roelen BAJ, Figueiredo JR. Expression of growth differentiation factor 9 (GDF9), bone morphogenetic protein 15 (BMP15), and BMP receptors in the ovaries of goats. Mol Reprod Dev. 2005; 70(1): 11-19.
3. Dewailly D, Robin G, Peigne M, Decanter C, Pigny P, Catteau-Jonard S. Interactions between androgens, FSH, anti-Müllerian hormone and es tradiol during folliculogenesis in the human normal and polycys tic ovary. Hum Reprod Update. 2016; 22(6): 709-724.
4. Carrell DT, Peterson CM. Reproductive endocrinology and infertility. New York: Springer; 2010; 345.
5. Qin Y, Zhao H, Xu J, Shi Y, Li Z, Qiao J, et al. Association of 8q22. 3 locus in Chinese Han with idiopathic premature ovarian failure (POF). Hum Mol Genet. 2011; 21(2): 430-436.
6. Tinjić S, Abazović Dž, Ljubić D, Vujović S, Vojvodić D, Božanović T, et al. Ovarian rejuvenation. Donald School J Ultrasound Obs te Gynecol. 2019; 13(2): 64-68.
7. Ljubić A, Abazović D, Vučetić D, Ljubić D, Pejović T, Božanović T. Case report autologous ovarian in vitro activation with ultrasound-guided orthotopic re-transplantation. Am J Clin Exp Obs tet Gynecol. 2017; 4(5): 51-57.
8. He Y, Chen D, Yang L, Hou Q, Ma H, Xu X. The therapeutic potential of bone marrow mesenchymal s tem cells in premature ovarian failure. S tem Cell Res Ther. 2018; 9(1): 263.
9. Evers JLH. Female subfertility. Lancet. 2002; 360(9327): 151-159.
10. Kaspers GJ, Veerman AJ, Popp-Snijders C, Lomecky M, Van Zantwijk CH, Swinkels LM, et al. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblas tic leukemia. Med Pediatr Oncol. 1996; 27(2): 114-121.
11. Labarta E, de Los Santos MJ, Escriba MJ, Pellicer A, Herraiz S. Mitohondria as a oocyte rejuvenation. Fertil S teril. 2019; 111(2): 219-226.
12. Hayashi K, Hikabe O, Obata Y, Hirao Y. Recons titution of mouse oogenesis in a dish from pluripotent s tem cells. Nat Protocol. 2017; 12(9): 1733-1744.
13. Hikabe O, Hamazaki N, Nagamatsu G, Obata Y, Hirao Y, Hamada N, et al. Recons titution in vitro of the entire cycle of the mouse female germ line. Nature. 2016; 539(7628): 299-303.
14. Morohaku K, Tanimoto R, Sasaki K, Kawahara-Miki R, Kono T, Hayashi K, et al. Complete in vitro generation of fertile oocytes from mouse primordial germ cells. Proc Natl Acad Sci USA. 2016; 113(32): 9021-9026.
15. Friedens tein AJ, Chailakhyan RK, Gerasimov UV. Bone marrow os teogenic s tem cells: in vitro cultivation and transplantation in diffusion chambers. Cell Tissue Kinet. 1987; 20(3): 263-272.
16. Liu T, Huang Y, Guo L, Cheng W, Zou G. CD44+/CD105+ human amniotic fluid mesenchymal s tem cells survive and proliferate in the ovary long-term in a mouse model of chemotherapy-induced premature ovarian failure. Int J Med Sci. 2012; 9(7): 592-602.
17. Xiao GY, Liu IH, Cheng CC, Chang CC, Lee YH, Cheng WTK, Wu SC. Amniotic fluid s tem cells prevent follicle atresia and rescue fertility of mice with premature ovarian failure induced by chemotherapy. PLoS One. 2014; 9(9): e106538.
18. Su J, Ding L, Cheng J, Yang J, Li X, Yan G, et al. Transplantation of adipose-derived s tem cells combined with collagen scaffolds res tores ovarian function in a rat model of premature ovarian insufficiency. Hum Reprod. 2016; 31: 1075-1086.
19. Wang Z, Wang Y, Yang T, Li J, Yang X. S tudy of the reparative effects of mens trual-derived s tem cells on premature ovarian failure in mice. S tem Cell Res Ther. 2017; 8(1): 11.
20. Lai D, Wang F, Yao X, Zhang Q, Wu X, Xiang C. Human endometrial mesenchymal s tem cells res tore ovarian function through improving the renewal of germline s tem cells in a mouse model of premature ovarian failure. J Transl Med. 2015; 13(1): 155.
21. Zhu SF, Hu HB, Xu HY, Fu XF, Peng DX, Su WY, et al. Human umbilical cord mesenchymal s tem cell transplantation res tores damaged ovaries. J Cell Mol Med. 2015; 19: 2108-2117.
22. Elfayomy AK, Almasry SM, El-Tarhouny SA, Eldomiaty MA. Human umbilical cord blood-mesenchymal s tem cells transplantation renovates the ovarian surface epithelium in a rat model of premature ovarian failure: possible direct and indirect effects. Tissue Cell. 2016; 48(4): 370-382.
23. Adler DS, Lazarus H, Nair R, Goldberg JL, Greco NJ, Lassar T, et al. Safety and efficacy of bone marrow-derived autologous CD133+ s tem cell therapy. Front Biosci (Elite Ed). 2011; 3: 506-514.
24. Bongiovanni D, Bassetti B, Gambini E, Gaipa G, Frati G, Achilli F, et al. The CD133+ cell as advanced medicinal product for myocardial and limb ischemia. S tem Cells Dev. 2014; 23(20) : 2403-2421.
25. Ahmadi H, Baharvand H, Ashtiani SK, Soleimani M, Sadeghian H, Ardekani JM, et al. Safety analysis and improved cardiac function following local autologous transplantation of CD133(+) enriched bone marrow cells after myocardial infarction. Curr Neurovasc Res. 2007; 4(3): 153-160.
26. Alvero R. Editorial: Challenging topics in reproductive endocrinology. Curr Opin Obs tet Gynecol. 2020; 32(5): 359-360.
27. Elkhenany HA, Szojka ARA, Mulet-Sierra A, Liang Y, Kunze M, Lan X, et al. Bone marrow mesenchymal s tem cells-derived tissues are mechanically superior to meniscus cells. Tissue Eng Part A. 2020 (ahead of print).
28. Kasapoğlu I, Seli E. Mitochondrial dysfunction and ovarian aging. Endocrinology. 2020; 161(2): bqaa001.
29. Petryk N, Petryk M. Ovarian rejuvenation through platelet-rich autologous plasma (PRP)—a chance to have a baby without donor eggs, improving the life quality of women suffering from early menopause without synthetic hormonal treatment. Reprod Sci. 2020; 27(11): 1975-1982.
30. Kawamura K, Kawamura N, Hsueh AJW. Activation of dormant follicles: a new treatment for premature ovarian failure? Curr Opin Obs tet Gynecol. 2016; 28(3): 217-222.